Utility of pre-procedural [Tc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [Tc]TcMAA-based Segmentation.

Purpose: Pre-treatment [Tc]TcMAA-based radioembolization treatment planning using multicompartment dosimetry involves the definition of the tumor and normal tissue compartments and calculation of the prescribed absorbed doses. The aim was to compare the real-world utility of anatomic and [Tc]TcMAA-based segmentation of tumor and normal tissue compartments.

Materials And Methods: Included patients had HCC treated by glass [Y]yttrium microspheres, ≥ 1 tumor, ≥ 3 cm diameter and [Tc]TcMAA SPECT/CT imaging before treatment.

SNMMI Clinical Trials Network Research Series for Technologists: An Introduction to Conducting Theranostic Clinical Trials.

This article is intended to introduce nuclear medicine technologists (NMTs) to the nuances of radiopharmaceutical therapy clinical trials. Here, we outline the potential roles and responsibilities of the NMT in clinical trials and provide context on different aspects of radionuclide therapy. The regulatory process involving investigational therapeutic radiopharmaceuticals is seldom taught to NMT students, nor is it included in the entry-level nuclear medicine certification examinations.

Y SIR-Spheres Activity Measurement with New SIROS D-Vial Delivery Kit.

A new Y SIR-Spheres delivery kit (SIROS D-vial and shield) has been introduced with a different physical form from the legacy V-Vial kit. Here, we establish the dose calibrator settings and exposure-rate-to-activity conversion factor to assay Y SIR-Spheres activity in the new SIROS kit. Eight D-vials with initial Y activities from 1.

Imageable Radioembolization Microspheres for Treatment of Unresectable Hepatocellular Carcinoma: Interim Results from a First-in-Human Trial.

Purpose: To determine 6-month interim safety, effectiveness, and multimodal imageability of imageable glass microsphere yttrium-90 (Y) radioembolization for unresectable hepatocellular carcinoma (HCC) in a first-in-human trial.

Materials And Methods: Imageable microspheres (Eye90 Microspheres; ABK Biomedical, Halifax, Nova Scotia, Canada), a U.S.

Resin-Based 90 Y Tumor Dose as a Predictor of Duration of Response and Survival in Patients With Surgically Unresectable Hepatocellular Carcinoma : A Prospective Single-Arm Study.

Background: Personalized dosimetry improves overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with glass 90 Y radioembolization. This study evaluated personalized tumor dose (TD) as a predictor of OS, progression-free survival (PFS), and local duration of response (DOR) in patients with surgically unresectable HCC treated with resin 90 Y radioembolization.

Patients And Methods: This prospective, single-center, single-arm clinical trial (NCT04172714) evaluated the efficacy of scout activity of resin 90 Y versus 99m Tc-MAA for treatment planning.